28585-51-5

2-Thiothymidine is a mRNA therapy used for treatment of ornithine transcarbamylase deficiency.

2-Thiothymidine is a hydrogen bond donor and acceptor that can be used as a substitute for thymine in the synthesis of DNA. 2-Thiothymidine has been shown to have successful in vivo treatment against bladder cancer and skin cells, as well as photochemical properties. It has been shown to inhibit the growth of prostate cancer cells by inhibiting DNA synthesis. 2-Thiothymidine binds to dna duplexes and polymerase chain reactions, which are important for replication of DNA. This drug also inhibits replication by preventing intramolecular hydrogen bonds from forming. 2-Thiothymidine is a nucleoside analog that is substituted for thymine during DNA synthesis. It inhibits the growth of prostate cancer cells by inhibiting DNA synthesis. It binds to dna duplexes and polymerase chain reactions, which are important for replication of DNA. This drug also inhibits replication by preventing intramolecular hydrogen bonds from forming.

2-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc